Windlas Biotech Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 31 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.0K Cr
Windlas Biotech aims for continued growth across its three verticals: CDMO, Trade Generics & Institutional, and Exports. FY '26 performance showed strong growth with revenue at INR 904 crores, 19% YoY increase, and EBITDA margin at ~13.4%.
From Windlas Biotech Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹994
Market Cap
₹2.0K Cr
P/E Ratio
29.5
How does Windlas Biotech Ltd rank in Pharmaceuticals & Biotechnology?
Compare Windlas Biotech Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Windlas Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹16 Cr.
Full financials →📊 Revenue & Sales Performance
- →Windlas Biotech aims for continued growth across its three verticals: CDMO, Trade Generics & Institutional, and Exports.
- →The company targets 18-20% historical growth rates, with potential to reach peak capacity utilization by FY '27.
- →Plant 6 commercialization by H1 FY '27 is expected to support revenue up to INR 1,100 crores, with a 10-15% capacity efficiency improvement possible.
- →Long-term growth in trade generics and institutional verticals driven by geographic expansion, portfolio enhancement, and new institutional accounts.
- →Export vertical expected to grow rapidly, backed by regulatory approvals and product registrations.
- →Management focuses on maintaining capacity efficiency and adding new products to fill gaps (e.g., codeine syrup replacement).
- →They maintain confidence in scaling operations without capacity being a bottleneck, aiming for strong volume and revenue growth.
📈 Profitability & Margins
- →FY '26 performance showed strong growth with revenue at INR 904 crores, 19% YoY increase, and EBITDA margin at ~13.4%.
- →Management expects continued growth across three verticals: CDMO, Trade Generics & Institutional, and Exports, with exports showing a 40% revenue rise in FY '26.
- →Profitability remains robust with FY '26 PAT at INR 83 crores (9.2% margin), and Q4 FY '26 PAT margin close to 9.7%.
- →The company emphasizes capacity efficiency improvements (10-15% possible beyond current capacity) to support growth without immediate large capex.
- →Capex focused on maintenance in FY '27, with potential growth-driven expansions expected from FY '28 based on utilization (~60% threshold).
- →Strong operational discipline and capital efficiency have sustained ROCE and ROE above 25%.
- →Overall, expects scale, deeper customer relationships, and high-margin export growth to drive earnings growth in the next 3-5 years.
🏗️ Capital Expenditure Plans
- →Plant 6 has achieved mechanical completion and is on track for commercialization by H1 FY '27.
- →Planned capex for FY '27 is mainly maintenance capex; no major organic capex expected in FY '27.
- →The company aims to maintain capacity efficiency and unlock 10-15% additional capacity without large new investments.
- →Further capacity expansions will be considered based on utilization; if utilization nears 60%, new capacity planning (possibly in FY '28) may commence.
- →Capital allocation strategy focuses on shorter-term capacity expansions (1.5 to 2.5 years) rather than large 5-year capacity builds.
- →Continuous investment in R&D for new product development and capability building is underway, driven by customer needs and market potential.
- →Increased investments in quality systems, compliance infrastructure, and talent to support regulatory demands and growth across injectables, exports, and complex generics.
💰 Fundraising & Capital Structure
- →No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
- →The company plans to focus on maintenance capex for FY '27, with no major organic capex planned aside from that.
- →Future capacity expansions or greenfield/brownfield capex will depend on utilization levels, expected around FY '28 or later.
- →Capital allocation strategy focuses on moderate 1.5 to 2.5 year capacity expansions rather than large long-term capex.
- →Management emphasizes financial discipline and balanced capital allocation, including shareholder returns such as buybacks and dividends.
- →No indications of needing external funding through equity or debt in the near term based on current growth and capex plans.
📋 Order Book & Pipeline
- →The transcript does not provide explicit current or expected order book or pending orders data for Windlas Biotech Limited.
- →However, management mentioned working with a strong pipeline of new ideas and product launches.
- →They focus on filling capacity with alternate products, e.g., replacing codeine syrup lost business.
- →Export vertical is seeing positive traction, but no specific order book numbers are disclosed.
- →Injectable ramp-up is progressing with regulatory approvals and customer onboarding underway.
- →The company is confident about scaling production with Plant 6 and expects to unlock additional capacity via efficiency improvements.
- →Overall, the approach emphasizes steady growth, diversification, and capital allocation discipline rather than large upfront order backlog.
Key Metrics
Continue your research
What Windlas Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Windlas Biotech Ltd Q4 FY26 results?
Windlas Biotech aims for continued growth across its three verticals: CDMO, Trade Generics & Institutional, and Exports. FY '26 performance showed strong growth with revenue at INR 904 crores, 19% YoY increase, and EBITDA margin at ~13.4%.
What is Windlas Biotech Ltd share price analysis?
Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.
Is Windlas Biotech Ltd planning capital expenditure?
Plant 6 has achieved mechanical completion and is on track for commercialization by H1 FY '27.
Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.